Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 15/20 | 0.58 |
| ▸ | AKR1C2 | P52895 | 15/20 | 0.58 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.40 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29509662 | 0.84 | AKR1C3 (0.44) | AKR1C3AKR1C2HTTNPSR1TPMT | |
| SCHEMBL6374729 | 0.83 | AKR1C3 (0.43) | AKR1C3AKR1C2AKR1C1PTGS1HTT | |
| SCHEMBL6374731 | 0.83 | AKR1C3 (0.43) | AKR1C3AKR1C2AKR1C1PTGS1HTT | |
| SCHEMBL7375255 | 0.83 | AKR1C3 (0.43) | AKR1C3AKR1C2AKR1C1PTGS1HTT | |
| SCHEMBL28322377 | 0.82 | AKR1C3 (0.42) | AKR1C3AKR1C2HTTNPSR1TPMT | |
| SCHEMBL28032981 | 0.82 | AKR1C3 (0.46) | AKR1C3AKR1C2AKR1C1PTGS1AKR1B10 | |
| SCHEMBL1653534 | 0.81 | AKR1C3 (0.52) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL1801772 | 0.81 | AKR1C3 (0.52) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL7705115 | 0.79 | ALDH1A1 (0.56) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 | |
| SCHEMBL510548 | 0.79 | ALDH1A1 (0.56) | AKR1C3AKR1C2AKR1C1PTGS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035169-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-8044046-B2 | Medicaments for the treatment of chronic obstructive pulmonary disease | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2011-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035169-A1 | AEROSOL FORMULATION FOR THE INHALATION OF BETA-AGONISTS | ADRB1, ADRB2, ADRB3 | AKR1C3 344/4885AKR1C2 531/4885AKR1C1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.